RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FittingThe dose escalation can take longer as they will be dosing a single patient during the first two cycles until DLT is shown if not they keep dosing therefore they add more levels of dosing to the program so essentially they could end up with more cycles but I believe the cut off for the MTD will be at 560mg/m2 therefore the MTD can't be three times more than Docetaxel as per company their PDC at 230mg/m2 is equal to 100mg/m2 of docetaxel which is the therapeutic dosage for Docetaxel.
At best it will be a bit over twice the docetaxel's safe and therapeutic level which is a great result.
There is no valid reason to increase the dosage past those levels it will not only expose group of patients to unnecessary high dosage increaseing the risk for toxicity during phase 1 but also throughout the remaining phases.